Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition.
Antineoplastic Agents
/ chemical synthesis
Cell Death
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Dose-Response Relationship, Drug
Drug Design
Drug Screening Assays, Antitumor
Humans
Molecular Structure
Phthalazines
/ chemical synthesis
Protein Kinase Inhibitors
/ chemical synthesis
Structure-Activity Relationship
Vascular Endothelial Growth Factor Receptor-2
/ antagonists & inhibitors
Substituted phthalazines
VEGFR-2 kinase inhibitors
anti-proliferative
apoptosis
Journal
Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
20
7
2019
pubmed:
20
7
2019
medline:
31
7
2019
Statut:
ppublish
Résumé
In the designed compounds, either a biarylamide or biarylurea moiety or an N-substituted piperazine motif was linked to position 1 of the phthalazine core. The anti-proliferative activity of the synthesised compounds revealed that eight compounds (
Identifiants
pubmed: 31322015
doi: 10.1080/14756366.2019.1642883
pmc: PMC6691788
doi:
Substances chimiques
Antineoplastic Agents
0
Phthalazines
0
Protein Kinase Inhibitors
0
phthalazine
91Y28DM24N
KDR protein, human
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Pagination
1347-1367Références
BMJ. 2001 Jun 23;322(7301):1536-8
pubmed: 11420279
Cell Growth Differ. 2001 Jul;12(7):363-9
pubmed: 11457733
Microvasc Res. 2003 Sep;66(2):102-12
pubmed: 12935768
Semin Oncol. 1992 Dec;19(6):622-38
pubmed: 1462164
Bioorg Med Chem Lett. 2005 Aug 1;15(15):3519-23
pubmed: 15990302
Cancer Res. 2006 Dec 15;66(24):11851-8
pubmed: 17178882
Stem Cell Rev. 2006;2(2):93-102
pubmed: 17237547
Expert Opin Investig Drugs. 2007 Mar;16(3):367-79
pubmed: 17302531
Cancer Cell. 2007 Jul;12(1):66-80
pubmed: 17613437
Leukemia. 2008 Apr;22(4):808-18
pubmed: 18200035
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
J Med Chem. 2009 May 14;52(9):2629-51
pubmed: 19320489
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Curr Med Chem. 2009;16(16):1949-63
pubmed: 19519375
Eur J Med Chem. 2010 Aug;45(8):3504-10
pubmed: 20537434
Toxicol Appl Pharmacol. 2010 Dec 1;249(2):132-9
pubmed: 20832415
Eur J Med Chem. 2011 Jun;46(6):2043-57
pubmed: 21429632
Bioorg Med Chem Lett. 2012 Apr 15;22(8):2693-7
pubmed: 22450127
Anticancer Agents Med Chem. 2013 Jun;13(5):731-47
pubmed: 23094911
J Med Chem. 2012 Dec 27;55(24):10797-822
pubmed: 23098265
J Med Chem. 2013 Feb 28;56(4):1363-88
pubmed: 23145854
Eur J Med Chem. 2013 Oct;68:253-9
pubmed: 23981532
Semin Hematol. 2013 Oct;50(4):271-83
pubmed: 24246694
Bioorg Med Chem Lett. 2014 Feb 15;24(4):1236-8
pubmed: 24447849
Biochem Pharmacol. 2014 May 1;89(1):52-61
pubmed: 24565910
Hepatol Res. 2015 Oct;45(10):E1-E11
pubmed: 25472913
J Chem Inf Model. 2015 Mar 23;55(3):687-99
pubmed: 25654403
J Chem Theory Comput. 2011 Jul 12;7(7):2307-15
pubmed: 26606498
Cancer Res. 1988 Feb 1;48(3):589-601
pubmed: 3335022
J Med Chem. 1985 Mar;28(3):295-8
pubmed: 3973901